We are pleased to announce that Dr. Jerry Nepom, Director of the ITN, has received the 2017 George Eisenbarth Award, a prestigious honor in recognition of his career in research for type 1 diabetes (T1D). The award was presented to Dr. Nepom at the international Immunology of Diabetes conference, held in San Francisco in January. The award was established in 2013 upon the death of George Eisenbarth, a pioneer in the field of type 1 diabetes. Dr.
An expert panel sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, issued clinical guidelines to aid health care providers in early introduction of peanut-containing foods to infants to prevent the development of peanut allergy.
Abatacept (Orencia®; Bristol-Myers Squibb) did not reduce the number of new gadolinium-enhancing Magnetic Resonance Imaging (MRI) lesions in patients with relapsing-remitting multiple sclerosis compared to a placebo after 24 weeks.
The Immune Tolerance Network (ITN) opened up a new observational transplant trial, ALLTOL, with the enrollment of its first two participants at the University of California, San Francisco (UCSF) June 30, 2016. ALLTOL is a prospective cohort study to enroll “operationally tolerant” kidney and liver transplant recipients who have successfully discontinued immunosuppressive medications and continue to have normal function in their transplanted organ.
The 12 young liver transplant recipients in the Immune Tolerance Network’s WISP-R Study (Withdrawal of Immunosuppression in Pediatric Liver Transplant Recipients) show no immunological or histological signs of rejection four years after coming off all immunosuppressive medications. The data were published last week in Hepatology.
Reduced Hypoglycemic Events and Improved Glycemic Variability is Associated with C-peptide Preservation in New-Onset Type 1 Diabetes Patients in the T1DAL Study
Better blood glucose control is correlated with C-peptide preservation, a marker of natural insulin production, in individuals with type 1 diabetes who participated in the Immune Tolerance Network’s T1DAL Study [Inducing Remission in New Onset T1DM with Alefacept (Amevive®)].
Introducing peanut to young infants in the LEAP peanut allergy prevention study did not negatively impact duration of breast feeding, nutritional intake, or growth five years later. The data published last week in the Journal of Allergy and Clinical Immunology alleviate potential concerns about whether adding peanut to the diet of this very young population (age 4-11 to 60 months) could have had negative effects on growth and nutrition.
The ITN’s LEAP study won the Society for Clinical Trials David Sackett Trial of the Year Award for 2015. This award goes to a randomized clinical trial published in the previous year that supports substantial change in healthcare, reflects excellent methodology, and overcomes obstacles in implementation. Congratulations to the LEAP team for this recognition!